Skip to main content
Technologies

Therapy for Preeclampsia

ID: 2016-022 AXL Receptor Inhibition in the Treatment of Preeclampsia

ID: 2016-022
Principal Investigator: Juan Arroyo

Preeclampsia (PE) is a major cause of preterm birth worldwide. Gas6 is a vitamin K dependent protein and is increased in the serum of woman who become preeclamptic during a pregnancy. Gas6 has a high affinity for AXL receptors. BYU’s inventor discover that using an AXL inhibitor prevented preeclampsia symptoms from appearing in an animal model which led to a better pregnancy prognosis.


About the Market:

Preeclampsia (PE) is a pregnancy-induced hypertensive disorder without an effective treatment. PE is the leading cause of pregnancy-related morbidity and mortality in the US, affecting over 200,000 pregnant women and newborns annually, at a significant cost to the healthcare system and lifelong consequences. PE is characterized by the onset of hypertension and proteinuria and can lead to more serious complications, such as seizure (eclampsia) and HELLP syndrome associated with systemic organ failure and death in the mother. A narrowing and constricting of transplacental blood vessels interfere with the flow of essential nutrients to the fetus, resulting in serious developmental issues including fetal death. Current interventions to treat PE include magnesium sulfate as an anticonvulsant and antihypertensive drugs, which manage symptoms but do not target the underlying causes of the disease. In many cases, the fetus must be delivered early, posing great risk to the health and survival of both the parent and fetus. PE affects 3-8% of all pregnancies worldwide.

For more information, contact Mike Alder (801-422-3049)

Links and Resources

  1. One Page Summary PDF
  2. Radio Broadcast - Aired June 14, 2016
  3. Inventor Webpage - Juan Arroyo
  4. Arroyo Lab Webpage